Welcome to our dedicated page for Apimeds Pharmaceuticals US SEC filings (Ticker: APUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Apimeds Pharmaceuticals US, Inc. filings document a Delaware clinical-stage biopharmaceutical issuer with common stock registered on NYSE American under APUS and emerging growth company status. Recent 8-K and 12b-25 records cover material definitive agreements, governance and executive changes, shareholder written-consent and voting matters, preferred stock and convertible-note conversion disclosures, and capital-structure matters.
The filing record also includes notices tied to delayed Form 10-K reporting and NYSE American continued-listing compliance, along with disclosures related to settlement agreements and merger-related governance matters. Periodic and event filings frame Apimeds' operating and financial results, risk factors, and clinical or regulatory disclosures for the Apitox program.
Apimeds Pharmaceuticals US, Inc. (APUS) entered into a First Amendment to its Confidential Settlement and Mutual Release Agreement on September 10, 2026, modifying how its board of directors is structured. During the interim period before the Preferred Stock Conversion, the board will consist solely of Elona Kogan, Carol O’Donnell, Dr. Bennett Weintraub, and Sungjoon Chae, and none of these directors may be removed without the written consent of Dr. Vin Menon and the Inscobee Parties.
After this interim period, the board is set at seven members: four independent directors nominated by MindWave, two directors nominated by Menon (including Menon), and Sungjoon Chae. On September 10, 2026, the board appointed Sungjoon Chae, already Co-Chief Executive Officer since May 2026, as a director; the company states there are no related party transactions or family relationships involving him, and his director compensation terms will be disclosed once finalized.
Apimeds Pharmaceuticals US, Inc. (APUS) entered into an Assignment and Transfer Agreement with FreeT Inc. on August 19, 2026 to acquire certain Apitox-related rights previously held by FreeT under a 2015 agreement. The Assigned Rights include 100% of rights to the Apitox market for Korean medicine clinics in Korea, a 25% royalty entitlement on economic proceeds from Apitox development, licensing, sale or other commercialization in the United States, and a 25% revenue participation right on net proceeds from overseas rights agreements. Apimeds also receives specified information and data/technology-related contractual benefits, while expressly not acquiring underlying Apitox intellectual property or any global rights not held by FreeT. Apimeds assumes only post-effective-date obligations directly tied to exercising these rights, and FreeT indicates it will use commercially reasonable efforts to support future global Apitox rights transactions, subject to separate definitive agreements. The agreement is governed by the laws of the Republic of Korea with exclusive jurisdiction in the Seoul Central District Court.
Apimeds Pharmaceuticals US, Inc. reported a net loss of $55.2 million for the six months ended June 30 2026, compared with $3.1 million a year earlier. Results reflect its dual structure: a clinical-stage BioBusiness developing APITOX for osteoarthritis pain and a Digital Asset segment holding Bitcoin, Tether and NILA tokens.
Digital assets were carried at $116.7 million, or 89% of total assets, and generated an unrealized loss of $35.3 million as prices declined, partially offset by realized and trading gains and $0.3 million of digital asset yield income. Operating expenses rose sharply, including $16.6 million of general and administrative costs with an $8.1 million non-cash advisory share charge and higher legal, advisory and public-company expenses.
Liquidity is strained: cash and cash equivalents were $278,371 with $8.0 million in restricted cash, while $5.0 million of short-term notes and a $10.9 million senior secured convertible note were current obligations. The company disclosed substantial doubt about its ability to continue as a going concern, is in discussions to extend or restructure debt, and faces NYSE American continued-listing risk after prior filing delays. A 1‑for‑10 reverse stock split became effective July 24 2026.
Apimeds Pharmaceuticals US, Inc. appointed Dr. Christopher Kim as Chief Scientific Officer, effective August 5, 2026. In this role, he will lead scientific, clinical, and regulatory development of the company’s APITOX program, including research and development, clinical strategy, and regulatory engagement.
The company states that Dr. Kim has been closely associated with APITOX for many years and has extensive scientific, technical, and regulatory expertise. His appointment is described as providing leadership continuity and supporting the company’s long-term strategy to advance APITOX through the regulatory process and toward commercialization.
Apimeds Pharmaceuticals US, Inc. will implement a 1-for-10 reverse stock split of its issued and outstanding common stock. The company plans to file a charter amendment with the Delaware Secretary of State on or about July 23, 2026, and has set the reverse split to become effective as of 12:01 a.m. Eastern Time on July 24, 2026.
Following effectiveness, every ten shares of common stock will automatically be combined into one share, and the stock is expected to begin trading on a split-adjusted basis on the NYSE American under the symbol APUS at the open of trading on July 24, 2026. The new CUSIP for the common stock will be 03771D201. Stockholders previously approved the reverse split by majority written consent on December 1, 2025, after which an information statement was mailed and the required waiting period has elapsed.
Apimeds Pharmaceuticals US, Inc. reported a net loss of $35.1 million for the three months ended March 31, 2026, compared with $0.4 million a year earlier. The loss was driven mainly by a $22.1 million unrealized loss on cryptocurrency holdings and a one-time $8.1 million non-cash stock charge for shares owed to its financial advisor.
The company, which has no revenue and is developing Apitox for knee osteoarthritis while also operating a digital asset segment, held digital assets at fair value of $127.8 million, down from $149.9 million at year-end 2025. Cash, cash equivalents and restricted cash totaled $9.0 million, with $2.1 million of cash used in operating activities in the quarter.
Apimeds warns that recurring losses, reliance on a $120.9 million PIPE facility (of which $10.9 million has been drawn and $8.0 million is restricted), and uncertainty about future draws raise substantial doubt about its ability to continue as a going concern. Subsequent events include a settlement of merger-related disputes, a forbearance agreement on defaults under its senior secured convertible note, and new high-return promissory notes. Management also discloses material weaknesses in internal control over financial reporting, noting its disclosure controls were not effective.
Apimeds Pharmaceuticals US, Inc. notified the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 because it is finalizing the quarter-end financial statements and requires additional time. The company expects to file the Form 10-Q within the five-calendar-day extension permitted under Rule 12b-25.
Inscobee Inc. and Apimeds Inc., both based in Korea, report beneficial ownership of 2,099,747 and 4,316,618 Apimeds Pharmaceuticals US common shares, representing 16.7% and 34.3% of the class, respectively, based on 12,575,983 shares outstanding as of April 30, 2026.
The investors entered a Settlement Agreement, Side Letter and Forbearance Agreement resolving merger-related disputes, litigation and alleged events of default, and setting governance, voting, standstill and transfer restrictions. They granted an irrevocable proxy to two individuals to vote their shares on specified matters until certain NYSE listing and conversion events occur or July 30, 2026. After independent PCAOB-registered firms verified approximately 1,000 bitcoin connected to the merger, the investors state their prior concerns about these digital assets have been addressed.
Apimeds Pharmaceuticals US, Inc. announced that its board of directors appointed Sungjoon ChaeMay 4, 2026, following a nomination by a stockholder. The company states there are no other arrangements or understandings that led to his selection beyond this nomination.
There are no family relationships between Mr. Chae and any of the company’s officers or directors, and no related party transactions requiring disclosure under Item 404(a) of Regulation S-K. The material terms of his compensation have not yet been determined and will be disclosed once finalized.
Mr. Chae is an architect and urban designer focused on large-scale real estate development and urban regeneration, with experience coordinating complex projects across multiple stakeholders and aligning design objectives with financial viability, regulatory requirements, and market conditions.
Apimeds Pharmaceuticals US, Inc. filed its annual report describing a transformative merger with MindWave Innovations Inc., completed on December 1, 2025. MindWave became a wholly owned subsidiary, and its former stockholders will receive Company common and preferred stock representing 90.9% of Apimeds’ fully diluted equity.
The report centers on Apitox, a bee venom–based biologic being developed for knee osteoarthritis pain and inflammation, with longer-term potential in multiple sclerosis. Extensive Korean Phase I–III data and a 3,194‑patient post‑marketing safety study support further U.S. development, including a new Phase III knee OA trial aimed at a future biologics license application.